
Novo Nordisk has generated a DKK 12bn (USD 1.8bn) profit in the third quarter of 2021, significantly more than for the same period last year, where the bottom line was DKK 10.3bn (USD 1.6bn), according to its report released on Wednesday morning.
For the first nine months of the year, net profit totals DKK 36.8bn (USD 5.7bn) compared to DKK 32.8bn (USD 5.1bn) at the same point last year. That is an increase of 12 percent, the report states.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.